<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Journey Medical Corp — News on 6ix</title>
    <link>https://6ix.com/company/journey-medical-corp</link>
    <description>Latest news and press releases for Journey Medical Corp on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 12:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/journey-medical-corp" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355cb078dffbe2df0ec6b2.webp</url>
      <title>Journey Medical Corp</title>
      <link>https://6ix.com/company/journey-medical-corp</link>
    </image>
    <item>
      <title>Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-secures-contract-with-third-major-gpo-for-emrositm</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-secures-contract-with-third-major-gpo-for-emrositm</guid>
      <pubDate>Tue, 21 Apr 2026 12:30:00 GMT</pubDate>
      <description>Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced</description>
    </item>
    <item>
      <title>Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-reports-full-year-2025-financial-results-and-recent-corporate-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-reports-full-year-2025-financial-results-and-recent-corporate-highlights</guid>
      <pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
      <description>Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period</description>
    </item>
    <item>
      <title>Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-to-announce-year-end-2025-financial-results-on-march-25-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-to-announce-year-end-2025-financial-results-on-march-25-2026-1</guid>
      <pubDate>Wed, 18 Mar 2026 12:30:00 GMT</pubDate>
      <description>Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ETSCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the</description>
    </item>
    <item>
      <title>Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announces-publication-133000813</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announces-publication-133000813</guid>
      <pubDate>Wed, 10 Dec 2025 13:30:00 GMT</pubDate>
      <description>Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GL</description>
    </item>
    <item>
      <title>Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-reports-third-210100910</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-reports-third-210100910</guid>
      <pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
      <description>Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling a</description>
    </item>
    <item>
      <title>Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announce-third-133000894</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announce-third-133000894</guid>
      <pubDate>Wed, 05 Nov 2025 13:30:00 GMT</pubDate>
      <description>Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ETSCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced t</description>
    </item>
    <item>
      <title>Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-reports-combined-123000958</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-reports-combined-123000958</guid>
      <pubDate>Fri, 24 Oct 2025 12:30:00 GMT</pubDate>
      <description>FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults DFD-29 demonstrated superior efficacy in IGA success rates and inflammatory lesion counts versus both placebo and doxycycline (P&lt;0.001 for all comparisons) Poster Presented on Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, in Patients with Rosacea: A Pooled</description>
    </item>
    <item>
      <title>Journey Medical Corporation to Participate in October 2025 Investor Conferences</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-participate-october-123000370</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-participate-october-123000370</guid>
      <pubDate>Wed, 08 Oct 2025 12:30:00 GMT</pubDate>
      <description>SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical’s management team will participate in two October 2025 investor conferences. Details of the event</description>
    </item>
    <item>
      <title>Journey Medical Corporation to Participate in September 2025 Investor Conferences</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-participate-september-123000936</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-participate-september-123000936</guid>
      <pubDate>Wed, 03 Sep 2025 12:30:00 GMT</pubDate>
      <description>SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferen</description>
    </item>
    <item>
      <title>Journey Medical Corporation to Present at the Emerging Growth Conference</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-present-emerging-123000064</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-present-emerging-123000064</guid>
      <pubDate>Mon, 18 Aug 2025 12:30:00 GMT</pubDate>
      <description>SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday,</description>
    </item>
    <item>
      <title>Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-reports-second-200100697</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-reports-second-200100697</guid>
      <pubDate>Tue, 12 Aug 2025 20:01:00 GMT</pubDate>
      <description>Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutica</description>
    </item>
    <item>
      <title>Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-ring-nasdaq-123000739</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-ring-nasdaq-123000739</guid>
      <pubDate>Thu, 07 Aug 2025 12:30:00 GMT</pubDate>
      <description>SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the management team of Journey Medical will ring the closing bell at the Nasdaq MarketSite in Times Squ</description>
    </item>
    <item>
      <title>Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announce-second-200100577</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announce-second-200100577</guid>
      <pubDate>Tue, 05 Aug 2025 20:01:00 GMT</pubDate>
      <description>Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ETSCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announce</description>
    </item>
    <item>
      <title>Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announces-expanded-123000497</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announces-expanded-123000497</guid>
      <pubDate>Mon, 14 Jul 2025 12:30:00 GMT</pubDate>
      <description>Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment o</description>
    </item>
    <item>
      <title>Journey Medical to Join Russell 2000® and Russell 3000® Indexes</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-join-russell-2000-123000866</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-join-russell-2000-123000866</guid>
      <pubDate>Tue, 24 Jun 2025 12:30:00 GMT</pubDate>
      <description>SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effec</description>
    </item>
    <item>
      <title>Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announces-emrosi-123000613</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announces-emrosi-123000613</guid>
      <pubDate>Fri, 20 Jun 2025 12:30:00 GMT</pubDate>
      <description>Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treating rosaceaSCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved</description>
    </item>
    <item>
      <title>Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announces-emrosi-123000153</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announces-emrosi-123000153</guid>
      <pubDate>Mon, 09 Jun 2025 12:30:00 GMT</pubDate>
      <description>National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for</description>
    </item>
    <item>
      <title>Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/journey-medical-corp/news/fortress-biotech-reports-first-quarter-2025-financial-results-and-recent-corporate-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/fortress-biotech-reports-first-quarter-2025-financial-results-and-recent-corporate-highlights</guid>
      <pubDate>Thu, 15 May 2025 20:05:00 GMT</pubDate>
      <description>Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”),</description>
    </item>
    <item>
      <title>Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-reports-first-200100765</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-reports-first-200100765</guid>
      <pubDate>Wed, 14 May 2025 20:01:00 GMT</pubDate>
      <description>Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Cor</description>
    </item>
    <item>
      <title>Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025</title>
      <link>https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announce-first-200100974</link>
      <guid isPermaLink="true">https://6ix.com/company/journey-medical-corp/news/journey-medical-corporation-announce-first-200100974</guid>
      <pubDate>Wed, 07 May 2025 20:01:00 GMT</pubDate>
      <description>Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ETSCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced th</description>
    </item>
  </channel>
</rss>